PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer

NCT ID: NCT06652607

Last Updated: 2025-03-12

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 152 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2024-12-20
• Study Completion Date: 2028-04-30

Brief Summary

Prostate cancer remains the most common malignancy in men in Europe. Over the last two decades, the treatment landscape for both localized and metastatic prostate cancer has been revolutionized. For patients with metastatic castration-sensitive prostate cancer (mCSPC), the primary treatment objectives are to delay progression to metastatic castration-resistant prostate cancer (mCRPC) and to improve overall survival (OS). Although patients with PC may initially respond to androgen deprivation therapy (ADT), progression to castration resistance occurs in 10-20% of patients within 5 years.

Primary ADT has been the standard of care for over 50 years. However, recent advancements have shifted treatment from ADT monotherapy for all mHSPC/mCRPC patients to more intensive approaches, which include combinations of ADT with new androgen receptor pathway inhibitors (ARPIs), chemotherapy, or both, tailored to tumor characteristics such as metastatic burden.

In clinical practice, a reduction in prostatic specific antigen (PSA) levels from baseline is commonly used to monitor disease control, particularly in the castration sensitive phase (both early and metastatic). For patients with mCSPC, a decrease in PSA levels signifies that the treatment is effective. Moreover, the depth, time and duration of this PSA reduction are linked to better clinical outcomes, including OS. Although more patients achieved an optimal PSA response with intensified ADT (with ARPI or docetaxel), those with a suboptimal response have a significantly worse survival rate. Several key studies have demonstrated that achieving undetectable PSA (≤0.2 ng/mL) is associated with better OS, irrespective of subgroups.

This study aims to evaluate patient survival based on PSA response and to describe baseline characteristics among patients with or without PSA response. Specifically, patients will be divided into two groups based on the achievement of PSA values ≤ 0.2 ng/dl, and overall survival (OS) and progression free survival (PFS) for each group will be evaluated. Clinical and laboratory information at baseline will be compared between the two groups. Baseline characteristics considered are histology, Gleason score, stage of disease, presence of genetic alterations, PSA values, sites and number of metastases, de novo or metachronous disease, high/low risk disease, high/low volume disease.

Conditions

Prostate Cancer; Metastatic Cancer; Castrate Sensitive Prostate Cancer

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Interventions

Enzalutamide

The objective of the study is to assess survival in patients treated with Enzalutamide according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.

Intervention Type: DRUG

Apalutamide (Erleada™) 60 mg or 240 mg tablets

The objective of the study is to assess survival in patients treated with Apalutamide according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.

Intervention Type: DRUG

Darolutamide (Nubeqa®) 300 mg tablets

The objective of the study is to assess survival in patients treated with Darolutamide according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.

Intervention Type: DRUG

Taxotere (docetaxel)

The objective of the study is to assess survival in patients treated with Taxotere according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.

Intervention Type: DRUG

Abiraterone acetate + Prednisone or Prednisolone

The objective of the study is to assess survival in patients treated with Abiraterone according to PSA response and to describe the baseline characteristics of patients with and without an optimal PSA response.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Aged ≥ 18 years old;
• Men with histologically or cytologically confirmed adenocarcinoma of the prostate with evidence of metastases;
• ECOG performance status ≤2;
• Staging of disease with TC + bone scintigraphy or with PET PSMA/choline;
• Availability of baseline PSA and after six months (±1) from the beginning of the ADT;
• Ongoing or completed treatment with at least one ARPI among abiraterone acetate, apalutamide, darolutamide and enzalutamide;
• Adequate information about baseline demographic, biological, clinical and laboratory data;
• Signed informed consent form, or declaration in lieu of informed consent form, if applicable.

Exclusion Criteria

• Patients without evidence of histological diagnosis of prostate cancer;
• No follow up visit after the beginning of therapy;
• No availability of baseline informations.

• Minimum Eligible Age: 18 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Roberto Iacovelli

Role: PRINCIPAL_INVESTIGATOR

Fondazione Policlinico Universitario A. Gemelli, IRCCS

Locations

Fondazione Policlinico Universitario A. Gemelli IRCCS, UOC ONCOLOGIA MEDICA

Rome, Lazio, Italy

Site Status: RECRUITING

Countries

Italy

Central Contacts

Roberto Iacovelli

Role: CONTACT

roberto.iacovelli@policlinicogemelli.it

+390630157373

Facility Contacts

Roberto Iacovelli

Role: primary

roberto.iacovelli@policlinicogemelli.it

+390630151

Other Identifiers

7039

Identifier Type: -

Identifier Source: org_study_id